Praxis Precision Medicines, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 24.63 million compared to USD 43.95 million a year ago. Basic loss per share from continuing operations was USD 2.7 compared to USD 14.4 a year ago.
For the nine months, net loss was USD 96.4 million compared to USD 172.86 million a year ago. Basic loss per share from continuing operations was USD 16.8 compared to USD 56.85 a year ago.